3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Lung Neoplasms
27
Neoplasms
7
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
4
Mesothelioma, Malignant
3
Melanoma
3
Colonic Neoplasms
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Mesothelioma
2
Meningeal Carcinomatosis
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Advanced Solid Tumors
2
Adenocarcinoma of Lung
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Carboplatin
2
repotrectinib
1
pembrolizumab
1
durvalumab
1
Pemetrexed
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Pemetrexed
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled